Novel therapeutic targets for cholestatic and fatty liver disease
M Trauner, CD Fuchs - Gut, 2022 - gut.bmj.com
Cholestatic and non-alcoholic fatty liver disease (NAFLD) share several key
pathophysiological mechanisms which can be targeted by novel therapeutic concepts that …
pathophysiological mechanisms which can be targeted by novel therapeutic concepts that …
The microbiota and the gut–liver axis in primary sclerosing cholangitis
JR Hov, TH Karlsen - Nature Reviews Gastroenterology & Hepatology, 2023 - nature.com
Primary sclerosing cholangitis (PSC) offers unique opportunities to explore the gut–liver axis
owing to the close association between liver disease and colonic inflammation. It is well …
owing to the close association between liver disease and colonic inflammation. It is well …
AASLD practice guidance on primary sclerosing cholangitis and cholangiocarcinoma
Abbreviations: AASLD, American Association for the Study of Liver Diseases; AIH,
autoimmune hepatitis; ALP, alkaline phosphatase; ASIR, age standardized incidence rate; …
autoimmune hepatitis; ALP, alkaline phosphatase; ASIR, age standardized incidence rate; …
Immunology of bile acids regulated receptors
Bile acids are steroids generated at the interface of host and intestinal microbiota. While
primary bile acids are generated in the liver from cholesterol metabolism, secondary bile …
primary bile acids are generated in the liver from cholesterol metabolism, secondary bile …
Protective and aggressive bacterial subsets and metabolites modify hepatobiliary inflammation and fibrosis in a murine model of PSC
Objective Conflicting microbiota data exist for primary sclerosing cholangitis (PSC) and
experimental models. Goal: define the function of complex resident microbes and their …
experimental models. Goal: define the function of complex resident microbes and their …
[HTML][HTML] Single-cell atlas of hepatic T cells reveals expansion of liver-resident naive-like CD4+ T cells in primary sclerosing cholangitis
T Poch, J Krause, C Casar, T Liwinski, L Glau… - Journal of …, 2021 - Elsevier
Background & Aims Little is known about the composition of intrahepatic immune cells and
their contribution to the pathogenesis of primary sclerosing cholangitis (PSC). Herein, we …
their contribution to the pathogenesis of primary sclerosing cholangitis (PSC). Herein, we …
The intestinal and biliary microbiome in autoimmune liver disease—current evidence and concepts
T Liwinski, M Heinemann, C Schramm - Seminars in Immunopathology, 2022 - Springer
Autoimmune liver diseases are a group of immune-mediated liver diseases with three
distinct entities, including autoimmune hepatitis, primary biliary cholangitis, and primary …
distinct entities, including autoimmune hepatitis, primary biliary cholangitis, and primary …
CD4+ T cells are required to improve the efficacy of CIK therapy in non-small cell lung cancer
S Liu, Y Meng, L Liu, Y Lv, W Yu, T Liu, L Wang… - Cell death & …, 2022 - nature.com
As a widely studied adoptive treatment method, CIK (cytokine-induced killer cells) treatment
has shown clinical benefits in many clinical trials on non-small cell lung cancer. As a …
has shown clinical benefits in many clinical trials on non-small cell lung cancer. As a …
[HTML][HTML] Single-cell, single-nucleus, and spatial transcriptomics characterization of the immunological landscape in the healthy and PSC human liver
Background & Aims Primary sclerosing cholangitis (PSC) is an immune-mediated
cholestatic liver disease for which there is an unmet need to understand the cellular …
cholestatic liver disease for which there is an unmet need to understand the cellular …
The liver as a central “hub” of the immune system: pathophysiological implications
The purpose of this review is to describe the immune function of the liver, guiding the reader
from the homeostatic tolerogenic status to the aberrant activation demonstrated in chronic …
from the homeostatic tolerogenic status to the aberrant activation demonstrated in chronic …